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 Hyperglycemia is considered the major determinant of
vascular complications and development of diabetic retinopa-
thy. The molecular mechanisms underlying such changes are
poorly understood. Nevertheless, there are some pathways
proposed to be involved in glucose toxicity, including nonen-
zymatic glycation, activation of protein kinase C, and increased
production of reactive oxygen species combined with impaired
antioxidative defenses [1,2]. In addition to nutrient supply,
the capillaries of the retina constitute a barrier to the passage
of blood-borne compounds and solutes between the blood and
the retina. In the inner retina, this barrier is comprised of mi-
crovascular endothelial cells and is known as the inner blood-
retinal barrier (BRB). The outer retina possesses another bar-
rier, the outer BRB, that consists of the retinal pigment epi-
thelial cells. Due to the presence of the BRB, glucose cannot
freely pass from blood to the retina. Glucose transport across
this barrier is mediated by a facilitative transporter, GLUT1
[3].
The regulation of GLUT1 in retinal endothelial cells in
response to chronic hyperglycemia is not clear. There are con-
flicting data concerning the effect of hyperglycemia on glu-
cose transport and on GLUT1 expression. In a diabetic ani-
mal model, Badr and colleagues showed a decrease of approxi-
mately 50% in whole retinal GLUT1 and retinal microvascu-
lar GLUT1, for 8 week-long diabetes [4]. Mandarino et al [5]
reported an unchanged uptake of 3-O-methylglucose (3-OMG)
in high glucose treated bovine retinal endothelial cells com-
pared with pericytes, which showed a downregulation in 3-
OMG uptake. In contrast, very recently, Busik et al [6] showed
an increase of glucose uptake in human retinal vascular en-
dothelial cells incubated under high glucose, without a change
in endothelial cell GLUT1.
The effect of diabetes on expression and regulation of the
GLUT1 glucose transporter in endothelial cells is evaluated
in this study. To investigate the regulation of GLUT1 levels in
BRB in response to hyperglycemia, we used two diabetic ani-
mal models and retinal endothelial cells. We demonstrate that
GLUT1 conjugation with ubiquitin may constitute a posttrans-
lational mechanism through which the cellular levels of
GLUT1 are regulated under hyperglycemia.
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Purpose: To investigate the effect of chronic hyperglycemia on the levels of the glucose transporter GLUT1 in retina and
its ubiquitinylation.
Methods: Two diabetic animal models (Goto Kakizaki rats and alloxan-induced diabetic rabbits) and retinal endothelial
cells in culture were used. GLUT1 content was determined by western blotting. Glut1 mRNA was determined by RT-PCR
and northern blotting. Ubiquitin conjugates were evaluated by western blot analysis. In vitro ubiquitin conjugation activ-
ity was evaluated in supernatants using radiolabeled ubiquitin. Evidence for GLUT1 ubiquitinylation was further investi-
gated by transfecting HEK293 cells with a hemagglutinin (HA)-tagged ubiquitin cDNA followed by immunoprecipitation
of the cell lysates.
Results: Chronic hyperglycemia resulted in a significant decrease on the amount of GLUT1 protein without significant
changes on the GLUT1 mRNA in the retinas of diabetic GK rats and alloxan treated rabbits, and in high glucose treated
retinal endothelial cells, compared to controls. The content of high molecular weight ubiquitin conjugates was higher both
in the membrane fractions of diabetic retinas and in endothelial cells incubated with high glucose concentrations. GLUT1
immunoprecipitated from diabetic retinas crossreacted with antibodies directed against ubiquitin suggesting that GLUT1
is posttranslationally modified by monoubiquitinylation. Cells transfected with HA-tagged ubiquitin revealed crossreactivity
with anti-GLUT1 antibodies on the HA immunoprecipitates.
Conclusions: The data indicate that retinal GLUT1 abundance decreases in experimental diabetes and with exposure of
retinal endothelial cells to elevated glucose concentrations. Results further suggest that decreased abundance of GLUT1
may be associated with its increased degradation by a ubiquitin dependent mechanism. Ubiquitinylation of GLUT1 may
be the mechanism targeting GLUT1 for degradation in diabetes.
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METHODS
Animals:  In this study two diabetic animal models were used,
the Goto Kakizaki (GK) rats and the alloxan-induced diabetic
rabbits. Wistar and GK rats were obtained from a local breed-
ing colony maintained at the University Hospitals of Coimbra.
After 6 weeks of age, the GK rats showed persistent hyperg-
lycemia. Six month old and one year old diabetic and age
matched nondiabetic Wistar control rats were used in these
experiments. The rats were fed normal rat chow ad libitum
and maintained in temperature-controlled facilities with 12 h
light-dark cycles. Glucose concentrations were measured on
tail blood samples using a glucose monitor (Gluco Touch;
Lifescan, Milpitas, CA).
Diabetes in rabbits was induced by the injection of a
freshly prepared solution of alloxan in serum at a dose of 110
mg/kg body in a prominent ear vein. A sample of blood was
obtained weekly from the ear vein to monitor glucose concen-
trations.
All animals were handled in accordance with ARVO State-
ment for the use of Animals in Opththalmic and Vision Re-
search.
Rats and rabbits were sacrificed by decapitation and their
eyes were quickly removed. Retinas were isolated and wrapped
in aluminum foil, frozen on liquid nitrogen and stored at -80
°C until used.
Primary cell cultures of bovine retinal endothelial cells:
Bovine retinas were the source of capillaries used to isolate
cells for primary culture. Cow eyes were obtained from a lo-
cal abattoir. Primary bovine retinal endothelial cells (BREC)
cultures were established from fresh calf eyes. Under sterile
conditions, the retinas were isolated and washed in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA)
and pieces of adherent retinal pigment epithelial cells were
removed. The retinas were transferred to an enzyme solution
containing pronase (100 µg/ml; Roche, Mannheim, Germany),
collagenase (500 µg/ml; Invitrogen) and DNase (70 µg/ml;
Sigma-Aldrich, St. Louis, MO) and incubated with shaking at
37 °C for 20 min. After incubation, the retinal digest was passed
through 210 and 50 µm nylon mesh and the microvessels
trapped on top of the 50 µm mesh were collected in DMEM
by centrifugation. The fragments were resuspended in DMEM
with 15% fetal calf serum (FCS), 20 µg/ml endothelial growth
supplement (Roche, Mannheim, Germany), heparin (100 µg/
ml) and antibiotic-antimycotic solution (Sigma, St. Louis,
MO), plated and grown on fibronectin coated dishes in low
glucose DMEM, at 37 °C with 5% CO2.
To determine the effect of high glucose on GLUT1 ex-
pression, BREC were grown in low (5.5 mM) or high (25 mM)
D-glucose medium up to 48 h.
Cell line of retinal capillary endothelial cells:  A condi-
tionally immortalized retinal capillary endothelial cell line (TR-
iBRB) [7] was grown and maintained in DMEM with low
glucose, containing 10% fetal bovine serum (FBS; Gibco BRL
Life Technologies, Inchiman, UK), 100 U/ml penicillin G, 100
U/ml streptomycin (Sigma), in a humidified atmosphere com-
posed of 95% air and 5% CO2 at 33 °C. Cells were grown to
approximately 40-50% confluence and incubated in regular
DMEM containing 5.5 or 25 mM glucose at 37 °C. Control
experiments using mannitol were performed to test the effect
of high osmolarity on the GLUT1 expression. There were no
changes in the GLUT1 expression in cells treated with 25 mM
mannitol for 48 h.
Human embryonic kidney (HEK)293 cells were cultured
in DMEM supplemented with 10% FBS, 100 U/ml penicillin
G, 100 U/ml streptomycin, in a humidified atmosphere com-
posed of 95% air and 5% CO2 at 37 °C.
Antibodies:  Goat polyclonal antibody raised against the
COOH terminus of rabbit GLUT1 was purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, California). Rabbit
polyclonal antibody raised against purified human erythro-
cyte GLUT1 was a kind gift from Christin Carter-Su. Mono-
clonal anti-ubiquitin antibody was purchased from Affiniti
Research Products Ltd. (Mamhead Castle, UK) and polyclonal
anti-ubiquitin antibody was a kind gift from Dr. Fu Shang
(Tufts University, Boston, MA). Mouse monoclonal antibody
against actin was purchased from Boehringer Mannheim
(Mannheim, Germany). Polyclonal anti-hemagglutinin anti-
body was purchased from Zymed Laboratories Inc. (South San
Francisco, CA).
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TABLE 1. BODY WEIGHT AND PLASMA GLUCOSE LEVELS FOR CONTROL
(WISTAR) AND DIABETIC (GK) RATS
                  Body weight   Serum glucose
              n       (g)          (mg/dL)
              -   -----------   -------------
Wistar rats
   6 months   5     552±40         121± 6
  12 months   4     811±42          91± 7
GK rats
   6 months   4     367±14*        267±34*
  12 months   4     423±52*        329±25*
Values in table are means±standard error. An asterisk (*) indicates a
stastically significant difference (p<0.01) between diabetic (GK) and
age matched control (Wistar) rats.
TABLE 2. BODY WEIGHT AND PLASMA GLUCOSE LEVELS FOR NONDIA-
BETIC AND DIABETIC RABBITS
                 Body weight    Serum glucose
             n       (g)           (mg/dL)
             -   ------------   -------------
Control      5     2420± 79        102± 3
Diabetic
  2 weeks    6     2575± 80        365±39
  2 months   7     3097±198        378±48
  4 months   7     3668± 95        332±27
Values in table are means±standard error. There were statistically
significant differences (p<0.01) for measurements of body weight
and serum glucose between diabetic (alloxan-induced) rabbits and
control rabbits.
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Isolation of the membrane fraction from the retina of dia-
betic and control animals:  Total retina homogenates from
diabetic or control animals were obtained by tissue lysis in 10
mM Tris-HCl, 1 mM EDTA, 250 mM sucrose, protease in-
hibitors, pH 7.4, at 4 °C and mechanical disruption using a
Potter-Elvehjem homogenizer (50-60 strokes). The samples
were centrifuged at 900x g to remove nuclei, mitochondria
and unlysed cells, and recentrifuged at 100,000x g for 75 min
to obtain the total cell membranes. The membrane pellet was
resuspended in 10 mM Tris-HCl, 1 mM EDTA, pH 7.4 con-
taining protease inhibitors, 0.5% sodium deoxycholate (DOC)
and 1% TritonX-100. The samples were then centrifuged at
14,000x g to remove the unsoluble fraction. The protein con-
centration was measured using the BCA reagent (Pierce, Rock-
ford, IL) with BSA as the standard.
Extracts from retinal endothelial cells (BREC and TR-
iBRB cells):  After incubation with glucose, the BREC and
TR-iBRB cells were washed twice with ice-cold PBS and then
lysed with 10 mM Tris-HCl, 1 mM EDTA, pH 7.4 containing
protease inhibitors, 0.5% DOC and 1% Triton X-100. The ly-
sates were sonicated 6 times for 3 s and then centrifuged at
14,000x g for 15 min. The supernatants were used to deter-
mine the protein concentration and were then denaturated with
Laemmli buffer.
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Figure 1. Effect of diabetes on GLUT1
expression in retina.  A: GLUT1 protein
expression in retina from 1 year old non-
diabetic rats is greater than in age
matched diabetic GK rats. Membrane
fractions were isolated from rat retinas.
Equal amounts of protein (30 µg) were
subjected to immunoblotting and mem-
branes were probed with anti-GLUT1
antibodies. Actin expression on the same
membrane is included to demonstrate
comparable loading of lanes. Graphical
summary and western blots are provided.
Bars represent standard errors (4 rats/
group). The asterisk (*) indicates that the
GLUT1 protein expression for 1 year old
diabetic GK rats are stastically different
from the age matched control Wistar rats
(p<0.05). B: GLUT1 protein expression
in diabetic rabbit retinas is decreased
compared to controls. The duration of
diabetes was 2 weeks, 2 and 4 months.
Membrane fractions were isolated from
rabbit retinas. Equal amounts of protein
(5 µg) were subjected to immunoblotting
and probed with antibodies directed
against GLUT1 and actin. Western blots
are provided. The graphic represents the
results normalized for actin. Bars repre-
sent standard errors (5 rabbits/group).
The asterisk (*) indicates that the GLUT1
protein expression for rabbits with-dia-
betes for 4 months are significantly dif-
ferent from the the control rabbits
(p<0.01). C: Slight increase on retinal
GLUT1 mRNA levels in diabetic ani-
mals. Total retinal RNA (1 µg or 150 ng)
was subjected to RT-PCR analysis for
determination of GLUT1 and actin
mRNA levels.    
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Isolation of total RNA from retina and TR-iBRB cells:
Total RNA was isolated from rat and rabbit retinas using
TRIzol® Reagent (Gibco BRL, Paisley, UK), according to
manufacturer’s protocol. Briefly, tissues were homogenized
in guanidium isothiocyanate and phenol. Chloroform extrac-
tion allowed recovery of RNA in the aqueous phase. The RNA
was then precipitated with isopropyl alcohol, and the RNA
pellet was washed with 75% ethanol and redissolved in DEPC
treated water. Total RNA samples were treated with RNase-
free DNase prior to reverse transcription to ensure that the
samples were free of contaminating DNA.
Total RNA from TR-iBRB cells was isolated using the
RNeasy mini kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocol.
The total amount of RNA was quantified by optical den-
sity (OD) measurements at 260 nm and the purity was evalu-
ated by measuring ratio of OD at 260 and 280 nm.
Western blotting:  For the western blot analysis, 5 to 30
µg protein were loaded per lane on sodium dodecyl sulphate-
polyacrylamide gels (SDS-PAGE). Following electrophore-
sis and transfer to polyvinylidene fluoride (PVDF) membranes
(Boehringer Mannheim), the blots were incubated in Tris buff-
ered saline (20 mM Tris, 137 mM NaCl, pH 7.6) containing
0.1% Tween 20 (TBST), and 5% nonfat milk for 1 h. Mem-
branes were then incubated with 1:1,000 dilution of affinity-
purified goat polyclonal anti-GLUT1 (Santa Cruz Biotech-
nology, Inc.), 1:10,000 dilution of rabbit polyclonal antibody
against GLUT1, 1:10,000 dilution of the anti-actin antibody,
or 1:1,000 dilution of mouse monoclonal (FK2) or polyclonal
antibodies to ubiquitinylated proteins, for 1 h 30 min, in TBST
containing 0.5% non fat milk. After five washes with TBST,
blots were reacted for 1 h with 1:10,000 dilution of secondary
antibodies coupled to alkaline-phosphatase in TBST contain-
ing 0.5% nonfat milk, and were then washed 5 times with
TBST and were developed using an enhanced fluorescence
kit (Amersham Pharmacia Biotech, Buckinghamshire, UK).
Blots were scanned in the Storm 860 (Molecular Dynamics,
Amersham Biosciences, Uppsala, Sweden) and the optical
density of the bands was measured with Image Quant 5.0 Soft-
ware (Molecular Dynamics). The intensity of the GLUT1
bands was normalized for every sample relatively to the in-
tensity of the respective actin bands.
Determination of ubiquitin conjugating activity:  The abil-
ity of TR-iBRB or retina supernatants to catalyse the conjuga-
tion of exogenous radiolabeled ubiquitin (125I) to endogenous
proteins was determined using an assay modified from Hershko
et al [8]. Briefly, cells or retinas were sonicated in 50 mM
Tris-HCl buffer, pH 7.6. The lysates were centrifuged at
14,000x g during 10 min, at 4 °C. Reactions were performed
in a final volume of 25 µl, containing 15 µl of supernatant (80
µg of TRi-BRB cell supernatant lysates or 50 µg of retina
supernatant lysates), 10 µl of conjugation buffer solution (50
mM Tris-HCl, pH 7.6, 5 mM MgCl2, 1 mM DTT, 2 mM ATP,
34.8 U/ml creatine phosphokinase, 10 mM creatine phosphate)
and 0.3 µg of 125I-ubiquitin (approximately 2 x 105 c.p.m).
Controls were generated by incubation with buffer A (50 mM
Tris-HCl, pH 7.6, 5 mM MgCl2 and 1 mM DTT). After 20
min of incubation at 37 °C, the reaction was terminated by the
addition of 25 µl of 2X Laemmli buffer followed by at least
30 min at room temperature. Aliquots of the assays were sepa-
rated by SDS/12%-PAGE. Autoradiograms of dried gels were
obtained and scanned for densitometric analysis.
Northern blotting:  Total RNA was isolated from control
and high glucose treated TR-iBRB cells. Aliquots (20 µg) of
total RNA were loaded on a 2 M formaldehyde 1% agarose
gel, and run overnight at 20 V. RNA was then transferred to a
nylon membrane (Schleicher & Schuell BioScience, Inc.,
Keene, NH) by capillary action for about 24 h. Northern blot
analysis for GLUT1 and mouse actin were performed as pre-
viously described [9], using a 512 kb PstI fragment of the
bovine blood-brain barrier glucose transporter cDNA [10] lin-
earized with HindIII, and a mouse actin clone, pAM-91 (gen-
erously provided by Michael J. Getz, Mayo Clinic/Founda-
tion, Rochester, MI), linearized with EcoRI. Both cDNAs were
labeled with [32P]-dCTP using a random primer method, as
described previously [9]. Quantification of autoradiograms was
performed using NIH Image software (version 1.6) and the
GLUT1 signal was normalized against the signal for actin.
Semi quantitative RT-PCR analyses:  GLUT1 mRNA lev-
els were determined by quantitative reverse transcription-PCR
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Figure 2. Effect of high glucose on
GLUT1 expression in primary cultures of
BREC cells.  In BREC cells exposed to
high glucose concentration there is a de-
crease in the amount of GLUT1 protein.
The cells were solubilized in Laemmli
buffer without β-Mercaptoethanol and
equal amounts of protein (30 µg) were
loaded on a 12% polyacrylamide gel fol-
lowing addition of reducing agent β-
Mercaptoethanol. The proteins were re-
solved by SDS-PAGE, transferred to
PVDF membrane and probed with an
antiserum against GLUT1. Coomassie
staining is used as a control for total pro-
tein loading.
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of total RNA from retinas, using the forward primer 5'-CTC
CAC GAG CAT CTT CGA GAA G-3' and the reverse primer
5'-TCA CAC TTG GGA ATC AGC CC-3' for amplification
of GLUT1, and the forward primer 5'-GAC TAC CTC ATG
AAG ATC CT-3' and the reverse primer 5'-ATC TTG ATC
TTC ATG GTG CTG-3' for amplification of actin.
For the RT-PCR reactions, 150 ng or 1 µg of total RNA
from rabbits and rats retinas, respectively, were used for
GLUT1 and actin amplification. Amplification products were
electrophoresed on 1% agarose gels and stained with ethidium
bromide. The gel was then photographed on a UV
transiluminator.
Transfection:  HEK293 cells were transiently transfected
with the plasmid encoding hemagglutinin-tagged ubiquitin,
under the control of the CMV promoter, which was kindly
donated by Dr. Bohmann, University of Rochester, Roches-
ter, NY. The transfection was carried out using
LipofectAMINE™ (Gibco BRL). Cells were incubated with
plasmid DNA for 6 h, and the same volume of fresh medium,
containing 10% FBS, was then added to the cells. Cells were
used 24 h after transfection.
Immunoprecipitation:  Immunoprecipitations were per-
formed by incubation of the protein extracts from retinas or
cells with the anti-GLUT1 (2.5 µg) or anti-HA (3.75 µg) anti-
bodies, overnight at 4 °C. The protein-antibodies complexes
were collected on protein G-Sepharose or protein A-Sepharose
beads. The beads were extensively washed and the immuno-
precipitated proteins were eluted in Laemmli buffer and re-
solved by SDS-PAGE.
Statistical analysis:  Measurements of the GLUT1 ex-
pression levels were averaged for each group of animals. A
minimum of three northern blot analysis was done for each
group of animals and a minimum of four measurements of
GLUT1 protein expression by western blot analysis was per-
formed. The mean values from each group were then used to
compute an overall mean and standard error of the mean. Com-
parisons between groups were made with an unpaired two
tailed Student’s t-test. The α level for statistical significance
was set at 0.05.
RESULTS
Animal and cell models of diabetes:  To establish the effect of
hyperglycemia on the expression of GLUT1, the level of
GLUT1 was analysed in two diabetic animal models and com-
pared to the level of expression of GLUT1 in control animals.
One of the diabetic animal models used was the GK rat,
which spontaneously develops non-insulin-dependent type 2
diabetes. These animals begin to develop chronic hyperglyce-
mia at 4 to 6 weeks of age [11] which remains stable during
ageing of the animals. Associated with hyperglycemia, these
animals present hyperinsulinemia, glucose intolerance and
some of the metabolic and anatomic changes similar to those
observed in human diabetic retinopathy [12-14]. The GK rats
were produced by selective breeding of normal Wistar rats
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Figure 3. Effect of high glucose on expression of GLUT1 in TR-iBRB cells.  A: In TR-iBRB cells exposed to high glucose concentration there
is a subnormal expression of GLUT1 protein. The cells were solubilized in SDS-PAGE buffer and equal amounts of protein (30 µg) were
loaded on a 12% polyacrylamide gel. The proteins were resolved by SDS-PAGE, transferred to PVDF membrane and probed with an antise-
rum against GLUT1. Bars represent standard errors (3 rats/group). The asterisk (*) indicates p<0.05. B: There are no significant changes in the
levels of GLUT1 mRNA after 48 h of hyperglycemia. The total RNA was isolated from control and high glucose treated TR-iBRB cells and
northern blot analysis was performed. Bars represent standard errors (3 rats/group).  
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and therefore the Wistar rats are considered appropriate con-
trols since these two groups of animals have the same genetic
background [11,15]. The second diabetic animal model used
was the alloxan treated rabbit that mimics type 1 diabetes.
Several reports showed retinal abnormalities such as
microaneurysms, pericyte loss, acellular capillaries [16] and
ultrastructural disorders of vessels and basement membrane
[17] in alloxan-induced diabetes.
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Figure 4. Effect of hyperglycemia on ubiquitinylation.  Hyperglycemia altered endogenous ubiquitin conjugates and de novo ubiquitin conju-
gation activity in diabetic animal (A, B) and in cells exposed to high glucose (C, D). Diabetic animals (A, lanes labeled “GK”) or cells exposed
to high glucose (C, right) show increased levels of endogenous high molecular weight ubiquitin conjugates. Cells exposed to high glucose also
show a significant decrease in the total amount of GLUT1 (C). Retinal tissues or cells were lysed, proteins were separated by SDS-PAGE,
transferred to PVDF membranes and probed with antibodies directed against ubiquitin conjugates (FK2). The increase in endogenous ubiquitin
conjugates is associated with an increased ability of retinal (B) or cell (D) extracts to conjugate radiolabeled 125I-ubiquitin to endogenous
substrates. Conjugation activity was determined either in the presence of an ATP generating buffer (“Buffer ATP” in B and D) or as a control
in the absence of ATP (“Buffer A” in B and D). Conjugation experiments were performed for 20 min. Proteins were resolved by SDS-PAGE
and the dried gels were used for autoradiography.      
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The average blood glucose concentrations and body
weight for the 6 months and 1 year old diabetic GK rats and
age matched Wistar rats are provided in Table 1. Data on dia-
betic rabbits and healthy controls are provided in Table 2. Dia-
betic rats were hyperglycemic and they failed to gain weight
at a normal rate. The average blood glucose concentrations
for diabetic rats and rabbits was significantly higher (p<0.01)
than that of control animals.
For this study, two retinal endothelial cell models were
used. A first approach to the effect of hyperglycemia on GLUT1
levels used primary cultures of endothelial cells obtained from
bovine retinas. Once glucose-related changes were established
in primary cultures, a cell line was used. TR-iBRB is a condi-
tionally immortalized retinal capillary endothelial cell line.
The cells present a doubling time of 19-21 h and exhibit the
properties of retinal capillary endothelial cells [7]. To mimic
the diabetic condition, both cell types were exposed to high
glucose.
Diabetic animals present lower levels of GLUT1 in retina:
To study the effect of chronic hyperglycemia on GLUT1 ex-
pression, we analysed the GLUT1 content in membrane frac-
tions isolated from the whole retinas of diabetic and control
animals (Figure 1). As a loading control, membranes were
probed with anti-actin antibody. At the age of 6 weeks before
GK rats developed diabetes, the Wistar and GK rats showed
comparable levels of GLUT1 and endogenous ubiquitin con-
jugates, thus indicating that the results obtained for older ani-
mals are not due to differences in the genetic background of
these animals (data not shown). Data presented in Figure 1A
indicate that there are no significant changes on GLUT1 pro-
tein levels between 6 months old WS rats (2.1±0.40) and GK
rats (2.2±0.30). For both control and diabetic rats, an age re-
lated decrease on the content of GLUT1 protein was observed.
However, GLUT1 expression was significantly lower in of 1
year old GK rats (1.2±0.33) as compared to the age matched
WS rats (1.7±0.28), p<0.05 level (Figure 1A).
A similar situation is observed in alloxan-induced dia-
betic rabbits. GLUT1 protein in the retina of non-diabetic rab-
bits is greater than that in diabetic rabbits (Figure 1B). Since
no age-related changes were observed in normal rabbits (data
not shown), only one time point was considered in Figure 1B
for control animals. To confirm that equal amounts of protein
were loaded on each lane, the membranes were stripped and
reprobed for actin. Diabetic animals with a duration of dis-
ease of 4 months presented a 50% decrease on the amount of
the glucose transporter in the retina (control rabbits: 5.7±0.50
and diabetic rabbits: 2.7±0.25; p<0.01).
The levels of GLUT1 mRNA were determined by RT-
PCR. Total RNA was isolated from whole retinas from rabbits
and rats and GLUT1 was amplified by RT-PCR (Figure 1C).
β-actin was amplified to confirm that equal quantities of RNA
were used for the amplification. There is no evidence for a
decrease on mRNA for GLUT1; therefore, the lower levels of
protein are probably the result of an increased degradation of
GLUT1 associated with diabetes.
High glucose results in a decrease in GLUT1 in retinal
endothelial cells:  As a first approach to study GLUT1 ex-
pression upon hyperglycemia, we used primary retinal endot-
helial cells in culture. BREC were incubated in the presence
of low (5.5 mM) and high (25 mM) glucose up to 48 h and
cells were then lysed and protein separated by SDS-PAGE,
transferred to PVDF membranes and probed with antibodies
against GLUT1 (Figure 2). After 48 h of incubation with high
glucose, there is a decrease of approximately 35% in the
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Figure 5. Evidence for ubiquitinylation of GLUT1 in vivo.  A: GLUT1
was immunoprecipitated from retinal lysates obtained from Wistar
(control) and GK (diabetic) rats. Proteins were resolved by SDS-
PAGE, transferred to PVDF membranes, and probed with antibodies
directed against ubiquitin conjugates (FK2). The additional band with
molecular weight around 60 kDa is compatible with a
monoubiquitinylated form of GLUT1. B: HEK cells were transfected
with multiubiquitin tagged to HA (Ub-HA). The cells were lysed and
their proteins were resolved by SDS-PAGE, transferred to PVDF
membranes, and probed with antibodies directed against HA. This
showed efficient transfection and formation of endogenous Ub-HA
conjugates had occurred. C: Immunoprecipitates of Ub-HA conju-
gates were subsequently probed with antibodies directed against
GLUT1. D: Samples were immunoprecipitated with anti-HA and
probed with antibodies directed against ubiquitin conjugates.  
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GLUT1 content as compared to control cells. This observa-
tion is consistent with the putative increase in GLUT1 degra-
dation observed in animal models of diabetes.
Considering the practical limitations associated with the
use of primary cultures of retina endothelial cells, we chose to
use the TR-iBRB, which have been described as a good model
for endothelial cells of inner blood-retinal barrier [7]. To in-
vestigate whether TR-iBRB would show a similar glucose-
dependent decrease of GLUT1, cells were incubated either in
the presence of 5.5 mM or 25 mM (hyperglycemia) glucose.
The proteins from TR-iBRB cells were separated by SDS-
PAGE, transferred to PVDF membranes and probed with an-
tibodies against GLUT1 (Figure 3A). The data are presented
as percentage of the control after 1 h of incubation. After 48 h
of incubation, cells treated with high glucose showed a sig-
nificant decrease (p<0.05) in the content of GLUT1
(90.6±7.08%) as compared to control cells (165±8.38%).
The expression of GLUT1 mRNA in high glucose treated
TR-iBRB cells was evaluated by northern blotting. The data
presented in Figure 3B show the amount of mRNA as per-
centage of controls after 1 h of incubation. There is no signifi-
cant change in the levels of GLUT1 mRNA between the cells
incubated in medium containing high and low glucose.
Diabetes is associated with increased ubiquitinylation of
retinal proteins:  The levels of GLUT1 of diabetic animals are
lower compared to control animals (Figure 1A,B) and incuba-
tion of cultured endothelial cells in hyperglycemic conditions
leads to a decrease on the GLUT1 expression (Figure 2, Fig-
ure 3A). However, in none of the tested conditions was there a
significant change in the levels of mRNA for GLUT1 (Figure
1C, Figure 3B). These data led us to hypothesize that the sta-
bility of GLUT1 is decreased in diabetes or under hypergly-
cemia. Since the ubiquitin conjugating system is one of the
proteolytic systems involved in regulating protein stability
[18,19], we looked for evidence of increased ubiquitinylation
in retinas of diabetic animals.
Membrane protein fractions from 6 months and 2 years
old GK and WS rats were separated by SDS-PAGE, trans-
ferred to PVDF membranes and probed with antibodies di-
rected against ubiquitin. The ubiquitinylated high molecular
weight conjugates were more abundant in the GK rats than in
age matched WS rats (Figure 4A). When TR-iBRB cells were
exposed to hyperglycemia for 15 days, a slight increase on the
total amount of endogenous high molecular weight ubiquitin
conjugates was observed, compared to those observed in
euglycemic conditions, with a paralleled decrease in the
GLUT1 content (Figure 4C), consistent with what was ob-
served for the animal models of diabetes (Figure 4A). The
endogenous ubiquitin conjugates were analysed after 15 days
of high glucose treatment since only at this time point a sig-
nificant increase in endogenous ubiquitin conjugates could be
observed whereas GLUT1 content decreases after 48 h of in-
cubation with high glucose (Figure 3A).
Conjugation of ubiquitin to GLUT1 is associated with in-
creased degradation of the protein in endothelial cells:  Since
data show that diabetes is associated with an increase on the
amount of ubiquitin-protein conjugates in the retina of rats
and in TR-iBRB cells exposed to high glucose, we further
investigated whether such an increase on ubiquitin-protein
conjugates is associated with an increase in the ability of reti-
nal endothelial cell lysates to conjugate exogenous ubiquitin
to endogenous substrates. Ubiquitin conjugating activity was
evaluated as the ability of retinal lysates to conjugate exog-
enous radiolabeled ubiquitin (125I-Ub) to endogenous sub-
strates. Data presented in Figure 4B show that retinal lysates
from diabetic animals present an increase of about 45% in the
ability to conjugate exogenous ubiquitin to endogenous sub-
strates. This increase in conjugation activity is reflected by
the accumulation of high molecular weight ubiquitinylated
proteins in retinas from diabetic animals (Figure 4B). The for-
mation of protein-ubiquitin conjugates is ATP-dependent, since
there are not any conjugates formed in the absence of ATP
(Figure 4B, compare “Buffer A” with “Buffer ATP”).
We further evaluated the ubiquitin conjugating activity
in the TR-iBRB cells exposed to high glucose. Consistent to
what was observed for retinas of diabetic animals, the cytoso-
lic fractions from TR-iBRB cells treated with high glucose
concentrations showed a higher ability (approximately 28%)
to form de novo ubiquitin conjugates as compared to cells
treated in euglycemic concentrations (Figure 4D).
Since the proteasome is inhibited during the conjugation
assays, the above data further suggest that the increase in en-
dogenous ubiquitin conjugates in hyperglycemic conditions
(GK rats and TR-iBRB cells treated with high glucose) is most
likely associated with an increase on the amount of substrates
prone to ubiquitinylation or an up-regulation of the activity
and/or conjugating enzymes.
To investigate a possible association between GLUT1 and
ubiquitin, the retinal membrane extracts from GK and WS rats
were used to immunoprecipitate (IP) GLUT1. Immunopre-
cipitated proteins were separated by SDS-PAGE, transferred
to PVDF and probed with antibodies directed against ubiquitin.
A band of molecular weight near 60 kDa was detected. Be-
cause ubiquitin has a molecular mass of 8.6 kDa, this 60 kDa
protein is likely to correspond to a monoubiquitinylated form
of GLUT1 since its molecular weight is consistent with the
addition of one ubiquitin molecule to GLUT1. Interestingly,
this band is more intense in the 2 year old animals (GK and
WS rats) than in the 6 month old rats (Figure 5A). This prob-
ably indicates that GLUT1 is ubiquitinylated in an age-de-
pendent way and that diabetes creates the conditions that fur-
ther lead to an enhanced conjugation of ubiquitin to GLUT1.
To further investigate the hypothesis that GLUT1 is
ubiquitinylated in vivo, we transfected HEK293 cells with a
HA-tagged ubiquitin cDNA, and the cell lysates were analysed
to confirm efficient ubiquitinylation of cell proteins with HA-
tagged ubiquitin (Figure 5B). The extracts were also used to
immunoprecipitate protein-ubiquitin conjugates with an anti-
body against the HA epitope. Proteins were resolved by SDS-
PAGE, transferred to PVDF, and the membrane was probed
with antibodies against GLUT1 (Figure 5C) or against
ubiquitin (Figure 5D). The immunoblot analysis showed that
GLUT1 is co-precipitated with ubiquitin-HA (Figure 5C). The
high molecular weight bands that cross reacted with the anti-
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GLUT1 antibody are likely to correspond to ubiquitinylated
GLUT1. A band of approximately 50 kDa, attributed to un-
modified GLUT1, is also present in the HA-ubiquitin immu-
noprecipitates. The presence of this band in HA
immunoprecitates may indicate that GLUT1 interacts in vivo
with a protein that is involved in the ubiquitin proteasome
pathway and that is most likely ubiquitinylated in vivo.
DISCUSSION
 The regulation of GLUT1 levels in retinal endothelial cells
subjected to chronic hyperglycemia remains a matter of con-
troversy, since there are conflicting reports in the literature
[4,6,20].
In this study, we used two different animal models of dia-
betes, as well as a primary culture of endothelial cells and a
cell line that expresses GLUT1. To mimic hyperglycemia en-
dothelial cells were exposed to high glucose, in order to clarify
the effect of diabetes on the level of expression of GLUT1.
We showed that the amount of GLUT1 present in membrane
fractions isolated from whole retinas of diabetic rats or rab-
bits is subnormal. Our data are in agreement with the results
reported by Tang et al [21], showing a decrease in GLUT1
expression in retinal vascular endothelium (55%) and in
homogenates of whole retina (36%) of streptozotocin-induced
diabetic rats. Consistently, the results of Badr et al. showed
that streptozotocin-induced diabetes reduced GLUT1 expres-
sion in the retina and its microvasculature by approximately
50% [4]. However, ultrastructural localization of GLUT1
showed increased expression of GLUT1 transporter in retinal
capillaries of three diabetic patients [20]. Apparently, such
contradictory observations could be due to the different ap-
proaches used to quantify GLUT1. In fact, as shown by the
present data, other studies in whole retinal vasculature
homogenates suggest a decrease in GLUT1 expression caused
by diabetes in several different diabetic models [4,21]. On the
other hand, ultrastructural localization of GLUT1 and quanti-
fication of GLUT1 sites at the capillary membranes detected
either increased GLUT1 levels [20] or no changes in GLUT1
levels [22] in diabetes. Taken together, these observations sug-
gest that the decrease on total pool of GLUT1 caused by dia-
betes (reported by Badr et al [4] and the present data) may not
limit GLUT1 targeting to plasma membranes but may result
in a reduction on the available pool of intracellular GLUT1
that could eventually compromise efficient recycling of the
transporter.
The observation that hyperglycemic conditions induce a
significant decrease on the amount of GLUT1 protein without
significant changes on the levels of its mRNA led us to hy-
pothesize that such decreased levels of GLUT1 may result
from an increase on the degradation rate of the protein. Alter-
ations in protein turnover during diabetes have been previ-
ously correlated with increased activity of the ubiquitin-de-
pendent proteolytic system in skeletal [23,24] and cardiac [25]
muscle. Moreover, the severity of electroneurographic changes
in patients with type 2 diabetes has been correlated with in-
creased serum ubiquitin levels [26]. Our results show that both
retinal extracts from GK rats and TR-iBRB cells treated with
high glucose present increased levels of ubiquitin conjugates
as compared to controls (Figure 4A,C). The increase in the
endogenous ubiquitin conjugates seems to be associated with
an increased ubiquitin conjugating activity as revealed by the
increased ability of tissue or cell extracts to conjugate exog-
enous ubiquitin to endogenous substrates (Figure 4B,D). This
suggests that, in agreement to what has been observed for other
tissues particularly affected by diabetes, there is an accumula-
tion of ubiquitin conjugates and an increase in the ubiquitin
conjugating activity in the retina during diabetes. Importantly
these alterations can be mimicked by exposing primary cul-
ture of endothelial cells or a retinal endothelial cell line to
high concentrations of glucose. The use of primary cultures of
retinal endothelial cells further showed that GLUT1 in endot-
helial cells responds to high glucose in a manner similar to
that observed for entire retinas of diabetic animals.
Since our data suggest increased degradation of GLUT1
during diabetes (Figure 1, Figure 2, and Figure 3) and since
we observed an increase on ubiquitin conjugates in hypergly-
cemic conditions, we tested whether ubiquitinylation is the
mechanism targeting GLUT1 degradation.
GLUT1 immunoprecipitated from membrane protein frac-
tions of control and diabetic rats cross-reacts with antibodies
to ubiquitin on western blots. This suggests that a ubiquitin-
like modification occurs in GLUT1, particularly in the older
(control and diabetic) animals. A more detailed evaluation of
the role of ubiquitinylation on targeting GLUT1 for degrada-
tion was performed in TR-iBRB cells.
The immunoprecipitates of ubiquitin-protein conjugates
from cells overexpressing hemagglutinin-tagged ubiquitin also
revealed crossreactivity with antibodies directed against
GLUT1. The presence in the HA-ubiquitin immunoprecipi-
tates of several bands that crossreact with anti-GLUT1 anti-
body could be due to the uncomplete processing of the con-
struct of multiubiquitins in the transfected cells. This approach
showed that GLUT1 is ubiquitinylated, but it does not allow
us to ascertain whether it is mono or polyubiquitinylated. We
suggest that ubiquitin is the triggering signal that targets the
glucose transporter GLUT1 for degradation either by lysos-
omes or proteasomes.
The ubiquitin proteasome pathway is involved in virtu-
ally all aspects of cell regulation [27]. The ubiquitin-depen-
dent proteolytic pathway involves covalent conjugation of
ubiquitin to substrates in a process dependent on ATP. Whereas
it has been clearly established that, in most cases, conjugation
of a protein to ubiquitin results in its degradation by the 26S
proteasome, it has more recently been suggested that
monoubiquininylation is associated with lysosomal degrada-
tion of targeted proteins [28,29].
More recently, several proteins have been identified as
being highly homologous to ubiquitin. Sentrin (or SUMO-1)
is a small ubiquitin-like protein [30]. To date only six main
substrates for sentrin have been characterized in mammalian
cells. Whereas it has been clearly established that in most cases
conjugation of a protein to ubiquitin results in its degradation
by the proteasome, it has more recently been suggested that
conjugation of sentrin to protein substrates, through Ubc9, is
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associated with changes in its subcellular distribution [31].
Recently it was shown that both GLUT1 and GLUT4 are modi-
fied by sentrin in skeletal muscle cells and that the specialized
conjugating enzyme, Ubc9, differentially regulates the cellu-
lar levels of the two GLUTs [32]. Overexpression of mUbc9
in these cells resulted in a decrease in GLUT1 abundance,
presumably by targeting the protein for degradation.
We show that GLUT1 is ubiquitinylated in the retina and
in endothelial cells and that aging and, significantly, diabetes
are associated with an increased ubiquitinylation of GLUT1.
By analogy to several other membrane proteins we can sug-
gest that GLUT1 is most likely monoubiquitinylated and pre-
sumably degraded by lysosomes.
In conclusion, ubiquitinylation plays a role in the regula-
tion of GLUT1 levels in endothelial cells in hyperglycemia
and may ultimately constitute a novel level of regulation
through which glucose transport into endothelial cells may
transduce pathophysiological changes associated with diabetic
retinopathy.
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